Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: There is increasing evidence that alterations in alternative splicing are linked to key tumor features in different cancers. Besides mutations, dysregulation of the splicing machinery would represent the main underlying cause for these alterations. Indeed, splicing dysregulation is emerging as a novel, transversal cancer hallmark, due to its association with multiple dysfunctions in tumor cells.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Alors-Pérez E
Authors: Alors-Pérez E, Pedraza-Arévalo S, Vázquez-Borrego M, Blázquez-Encinas R, Herrera-Martínez A,
Keywords: PanNET, CELF4, splicing, aggressiveness, pituitary tumors,
#3053 The Splicing Machinery Is Dysregulated in Low Grade Pulmonary Neuroendocrine Tumors
Introduction: Alternative splicing dysregulation is increasingly regarded as a novel cancer hallmark influencing all key tumor features. We have shown that neuroendocrine tumors (NETs) overexpress aberrantly spliced variants of neuropeptides and receptors that increase tumor malignancy. More recently, we discovered that the splicing machinery is dysregulated in pituitary and pancreatic NETs. To date, the status of this machinery in low grade pulmonary NETs is largely unknown.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Blázquez-Encinas R
Authors: Blázquez-Encinas R, Caro M, Pedraza-Arévalo S, Alors-Pérez E, Herrera-Martínez A,
Keywords: low grade pulmonary NETs, splicing, splicing machinery, malignancy,
Introduction: Atypical carcinoid and small cell lung cancer (SCLC) are currently incurable. There is thus a critical need for new diagnostic and therapeutic strategies for lung neuroendocrine neoplasms (LNEN). Chemokine receptor 4 (CXCR4), a G protein coupled receptor and theranostic target, plays a crucial role in metastases of LNEN. We hypothesize combination of thioredoxin reductase (TR) inhibitor represents a metabolic strategy to enhance cytotoxicity in peptide-receptor radionuclide therapy (PRRT) of LNEN.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Liu D
Authors: Liu D, Fath M, Robles Planells C, Balk E, Bellizzi A,
Keywords: CXCR4, thioredoxin reductase inhibitor, theranostics, atypical carcinoid, small cell lung cancer,
#3004 Development of Anti-SSTR CAR T Cells for Future Treatment of NETs
Introduction: NETs overexpress somatostatin receptors (SSTRs).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Cives M
Authors: Mandriani B, Cives M, Pelle' E, Quaresmini D, Ramello M,
Keywords: CAR T cells, adoptive cellular immunotherapy, NETs,
Introduction: The somatostatin-2 receptor (SST2) is a target for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NETs). By using epigenetic drugs, which can regulate gene transcription, PRRT efficacy may be further improved due to enhanced SST2 expression.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Klomp I
Authors: Klomp I, Dalm S, van Koetsveld P, Dogan-Oruç F, de Jong M,
Keywords: neuroendocrine tumors, bon-1, epigenetic, histone, histone deacetylase inhibitor, HDACi, upregulation, reversibility, somatostatin receptor-2, somatostatin,